Products
Retapamulin is commercially available as an ointment (Altargo). It was approved in the EU in 2007 and in many countries in 2009.
Structure and properties
Retapamulin is a semisynthetic derivative of pleuromutilin derived from the pillz (cat’s ear).
Effects
Retapamulin (ATC D06AX13) is bacteriostatic against and by inhibiting bacterial protein synthesis via ribosomal binding. The binding site differs from other antibiotics.
Indications
Retapamulin is used for short-term treatment of impetigo, infected minor skin lesions, abrasions, or sutured wounds.
Dosage
According to the professional information. The ointment is usually applied twice daily for 5 days.
Contraindications
Retapamulin is contraindicated in hypersensitivity and in infants younger than 9 months. Do not treat more than 2 percent of body surface area in patients younger than 18 years. Do not contact eyes or mucous membranes. Shall not be used to treat infections in which MRSA is known or suspected to be the causative agent. Should not be used to treat abscesses. For complete precautions, see the drug label.
Interactions
No interactions are known to date. Retapamulin is a potent inhibitor of CYP3A4. However, due to the low plasma concentrations, no interactions with systemically applied drugs are expected.
Adverse effects
Local skin reactions such as irritation, pain, itching, redness, and contact dermatitis may occur.
